WebApr 2, 2024 · Among all the drugs available, the compounds known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) appear to be not just innocuous in terms of CVD but indeed to be beneficial. GLP-1 RA actions not only translate on an improvement of well-known cardiovascular risk factors such as glycaemic control, dyslipidaemia, weight, or … WebApr 1, 2024 · Introduction. Management of type 2 diabetes mellitus (T2DM) has evolved from a glucocentric to a cardiometabolic approach [].Consequently, choosing anti-hyperglycemic therapies with proven cardiovascular and renal benefits is now a cornerstone of T2DM management [].Both glucagon-like peptide-1 receptor agonists …
After 10 Years and 26 CVOTs, Where do We Stand on CV …
WebCV Benefit* Dose Modification Indications Canagliflozin 100 mg PO daily • eGFR 30 to 59 ml/min/1.73m2: max dose 100 mg daily • eGFR <30 ml/min/1.73m2: use is not recommended for glycemic control • Improve glycemic control in adults with T2D as an adjunct to diet and exercise • Reduce risk of MI, stroke, or CV death in WebTwo new medication classes, glucagon-like peptide 1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i), have demonstrated cardiovascular and renal protective properties, creating a new way to care for patients with T2DM.Methods: This study evaluated the safety and efficacy of the combined use of GLP-1 RA and ... netflix twins movie
Real-world characteristics, modern antidiabetic treatment patterns, …
http://mdedge.ma1.medscape.com/fedprac/article/259527/diabetes/safety-and-efficacy-glp-1-receptor-agonists-and-sglt2-inhibitors/page/0/1 WebThe American Diabetes Association recommends medications with proven benefit in cardiovascular disease (CVD), such as the GLP-1 RAs liraglutide, injectable semaglutide, or dulaglutide, or the SGLT2i empagliflozin or canagliflozin, as second-line after metformin in patients with established atherosclerotic CVD or indicators of high risk to ... WebJun 18, 2024 · The increase in heart rate of 9 bpm at 3 months of treatment with once-weekly exenatide compared with placebo was more marked than that reported in clinical trials of GLP-1 RA associated with greater reductions in cardiovascular event rates (1,4,11).In light of the prognostic value of resting heart rate on cardiovascular outcomes … itv news local south west